{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:43Z","timestamp":1792404043307,"version":"4.4.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/ftd.0b013e3182381bb1","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T09:27:49Z","timestamp":1321694869000},"page":"735-741","source":"Crossref","is-referenced-by-count":19,"title":["Measurement of Posaconazole, Itraconazole, and Hydroxyitraconazole in Plasma\/Serum by High-Performance Liquid Chromatography With Fluorescence Detection"],"prefix":"10.1097","volume":"33","author":[{"given":"Sara L","family":"Buckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Mansour","family":"Ceesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip E","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/21.2.361","article-title":"Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukaemia: the pathogenic role of the antileukaemic regimen.","volume":"21","author":"Bow","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/41.suppl_4.1","article-title":"Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.","volume":"41","author":"Bow","year":"1998","journal-title":"Antimicrob Agents Ch"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies.","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2006.00805.x","article-title":"Evaluating prophylaxis if invasive fungal infections in patients with haematological malignancies.","volume":"78","author":"Maertens","year":"2007","journal-title":"Eur J Haematol"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0966-842X(97)01206-7","article-title":"Emerging targets for the development of novel antifungal therapeutics.","volume":"6","author":"Groll","year":"1998","journal-title":"Trends Microbiol"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jms.280","article-title":"Mechanism of azole antifungal activity as determined by liquid chromatographic\/mass spectrometric monitoring of ergosterol biosynthesis.","volume":"37","author":"Heimark","year":"2002","journal-title":"J Mass Spectrom"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis.","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Ch"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/01.qco.0000399603.91138.e7","article-title":"Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy.","volume":"24","author":"Lewis","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpba.2009.03.034","article-title":"A high-throughput LC-MS\/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography.","volume":"50","author":"Cunliffe","year":"2009","journal-title":"J Pharmaceut Biomed"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Ch"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/QCO.0b013e3283184611","article-title":"Therapeutic drug monitoring for triazoles.","volume":"21","author":"Hope","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug Monitoring.","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein.","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Ch"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Ch"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Ch"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogenic haematopoietic stem cell transplant recipients with graft-versus-host disease.","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.01027-09","article-title":"Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing stem cell transplantation.","volume":"54","author":"Kohl","year":"2010","journal-title":"Antimicrob Agents Ch"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS.","volume":"878","author":"Alfenaar","year":"2010","journal-title":"J Chromatogr B"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/FTD.0b013e3181e185fd","article-title":"Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum.","volume":"32","author":"Chahbouni","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","article-title":"Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection.","volume":"50","author":"Gordien","year":"2009","journal-title":"J Pharmaceut Biomed"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition.","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group.","volume":"46","author":"de Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.","volume":"32","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in patients after prophylaxis with itraconazole.","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers.","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Ch"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00240-09","article-title":"Posaconazole therapeutic drug monitoring: a reference laboratory experience.","volume":"53","author":"Thomson","year":"2009","journal-title":"Antimicrob Agents Ch"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Ch"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Ch"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Ch"},{"key":"R34-11-20210129","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Ch"},{"key":"R35-11-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Ch"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182381bb1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:16Z","timestamp":1620952756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201112000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182381bb1","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}